000852453 001__ 852453
000852453 005__ 20210129235057.0
000852453 0247_ $$2doi$$a10.1016/j.neuropharm.2017.04.011
000852453 0247_ $$2ISSN$$a0028-3908
000852453 0247_ $$2ISSN$$a1873-7064
000852453 0247_ $$2pmid$$apmid:28400256
000852453 0247_ $$2WOS$$aWOS:000403513800010
000852453 0247_ $$2altmetric$$aaltmetric:18791709
000852453 037__ $$aFZJ-2018-05399
000852453 082__ $$a610
000852453 1001_ $$0P:(DE-HGF)0$$aSergeeva, Olga A.$$b0$$eCorresponding author
000852453 245__ $$aN-oleoyldopamine modulates activity of midbrain dopaminergic neurons through multiple mechanisms
000852453 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2017
000852453 3367_ $$2DRIVER$$aarticle
000852453 3367_ $$2DataCite$$aOutput Types/Journal article
000852453 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1539670400_30352
000852453 3367_ $$2BibTeX$$aARTICLE
000852453 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000852453 3367_ $$00$$2EndNote$$aJournal Article
000852453 520__ $$aN-oleoyl-dopamine (OLDA) is an amide of dopamine and oleic acid, synthesized in catecholaminergic neurons. The present study investigates OLDA targets in midbrain dopaminergic (DA) neurons. Substantia Nigra compacta (SNc) DA neurons recorded in brain slices were excited by OLDA in wild type mice. In transient receptor potential vanilloid 1 (TRPV1) knockout (KO) mice, however, SNc DA neurons displayed sustained inhibition of firing. In the presence of the dopamine type 2 receptor (D2R) antagonist sulpiride or the dopamine transporter blocker nomifensine no such inhibition was observed. Under sulpiride OLDA slightly excited SNc DA neurons, an action abolished upon combined application of the cannabinoid1 and 2 receptor antagonists AM251 and AM630. In ventral tegmental area (VTA) DA neurons from TRPV1 KO mice a transient inhibition of firing by OLDA was observed. Thus OLDA modulates the firing of nigrostriatal DA neurons through interactions with TRPV1, cannabinoid receptors and dopamine uptake. These findings suggest further development of OLDA-like tandem molecules for the treatment of movement disorders including Parkinson's disease.
000852453 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000852453 536__ $$0G:(DE-HGF)POF3-571$$a571 - Connectivity and Activity (POF3-571)$$cPOF3-571$$fPOF III$$x1
000852453 588__ $$aDataset connected to CrossRef
000852453 7001_ $$0P:(DE-HGF)0$$aDe Luca, Roberto$$b1
000852453 7001_ $$0P:(DE-HGF)0$$aMazur, Karolina$$b2
000852453 7001_ $$0P:(DE-HGF)0$$aChepkova, Aissa N.$$b3
000852453 7001_ $$0P:(DE-HGF)0$$aHaas, Helmut L.$$b4
000852453 7001_ $$0P:(DE-Juel1)131672$$aBauer, Andreas$$b5
000852453 773__ $$0PERI:(DE-600)1500655-4$$a10.1016/j.neuropharm.2017.04.011$$gVol. 119, p. 111 - 122$$p111 - 122$$tNeuropharmacology$$v119$$x0028-3908$$y2017
000852453 8564_ $$uhttps://juser.fz-juelich.de/record/852453/files/N-oleoyldopamine%20modulates%20activity%20of%20midbrain%20dopaminergic%20neurons%20through%20multiple%20mechanisms.pdf$$yRestricted
000852453 8564_ $$uhttps://juser.fz-juelich.de/record/852453/files/N-oleoyldopamine%20modulates%20activity%20of%20midbrain%20dopaminergic%20neurons%20through%20multiple%20mechanisms.pdf?subformat=pdfa$$xpdfa$$yRestricted
000852453 909CO $$ooai:juser.fz-juelich.de:852453$$pVDB
000852453 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Medical Faculty of Heinrich-Heine University$$b0
000852453 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Medical Faculty of Heinrich-Heine University$$b1
000852453 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Medical Faculty of Heinrich-Heine University$$b2
000852453 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Medical Faculty of Heinrich-Heine University$$b3
000852453 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Medical Faculty of Heinrich-Heine University$$b4
000852453 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131672$$aForschungszentrum Jülich$$b5$$kFZJ
000852453 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)131672$$a Medical Faculty of Heinrich-Heine University$$b5
000852453 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000852453 9131_ $$0G:(DE-HGF)POF3-571$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vConnectivity and Activity$$x1
000852453 9141_ $$y2018
000852453 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000852453 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROPHARMACOLOGY : 2015
000852453 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000852453 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000852453 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000852453 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000852453 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000852453 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000852453 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000852453 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000852453 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000852453 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000852453 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000852453 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000852453 920__ $$lyes
000852453 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000852453 980__ $$ajournal
000852453 980__ $$aVDB
000852453 980__ $$aI:(DE-Juel1)INM-2-20090406
000852453 980__ $$aUNRESTRICTED